Xinjiang Uyghur Autonomous Region Infectious Disease Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pei, Yi
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Recruiting
4
45
RoW
BDL regimen
Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center
Pulmonary Tuberculosis
06/25
06/26
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Recruiting
4
212
RoW
Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide
Beijing Chest Hospital
Tuberculosis, Multidrug-Resistant
08/25
08/25
INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort

Not yet recruiting
3
120
RoW
bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C
Huashan Hospital, Beijing Chest Hospital
Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
06/27
06/27
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort

Recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy

Not yet recruiting
1
72
RoW
Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT)
Healthgen Biotechnology Corp.
Pleurisy
07/25
12/25

Download Options